Akadeum Life Sciences, an Ann Arbor, MI-based company which specializes in buoyancy-based cell separation technology, raised $20M+ in funding.
The round was led by Michigan Capital Network, with participation from Arboretum Ventures, NYBC Ventures, and other investors.
The company intends to use the funds to scale commercial operations and especially support customers entering clinical trials.
Led by CEO and Founder Brandon McNaughton, Akadeum Life Sciences develops flotation-based separation technologies that enable the cell isolation. It has introduced innovations including scalable negative selection, multiplex separation, microbubble-based nucleic acid extraction, and a T cell separation chamber. Its proprietary platform has already demonstrated therapeutic relevance, including successful use in preclinical animal models for cancer treatment, and is poised for broader adoption in human cell therapy pipelines.
Akadeum received interest from biopharma providers and partners including Catalent, Charles River Laboratories, ElevateBio, and Lonza, who have featured Akadeum’s technology in recent conference talks and poster sessions.
FinSMEs
04/06/2025